Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 207-662-1 | CAS number: 487-68-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Link to relevant study records
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant near-guideline study, available as unpublished report, minor restrictions in design and/or reporting but otherwise adequate for assessment.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
- Species / strain / cell type:
- mammalian cell line, other: Chinese Hamster Lung (CHL/IU)
- Details on mammalian cell type (if applicable):
- - Type and identity of media: Neonatal calf serum (Lot No. NBQ07, Mitsubishi Chemical Corporation) was added to Eagle MEM medium (Lot No. 421001, Nissui Pharmaceutical Co., Ltd.) at 10 v/v%.
- Periodically checked for Mycoplasma contamination: yes
- Periodically "cleansed" against high spontaneous background: yes - Metabolic activation:
- with and without
- Metabolic activation system:
- Phenobarbital and 5,6-benzoflavone induced SD rats rat liver S9-mix
- Test concentrations with justification for top dose:
- Chromosomal aberration study: 0, 40, 80, 160 µg/mL in the absence of S9 mix and 0, 70, 140, 280 µg/mL in the presence of S9 mix.
Chromosomal aberration study (confirmatory study): 0, 80, 110, 140 µg/mL in the absence of S9 mix and 0, 140, 200, 260 µg/mL in the presence of S9 mix. - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle: This solvent was selected because the test substance was found to be dissolved at 150 mg/mL or more in DMSO. - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- mitomycin C
- Remarks:
- In the absence of metabolic activation
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- In the precence of metabolic activation
- Details on test system and experimental conditions:
- CELL GROWTH INHIBITION TEST: A preliminary toxicity test was performed on cell cultures using a 6-hour exposure period (both with and without metabolic activation) followed by an 18-hour recovery period in treatment-free media. The dose range used was 20 to 360 µg/mL.
CHROMOSOMAL ABERRATION STUDY:
EXPERIMENT 1
- METHOD OF APPLICATION: in medium
- DURATION: A chromosomal aberration study was conducted in the same way as the cell growth inhibition study.
- DOSE LEVELS SELECTED FOR METAPHASE ANALYSIS: Chromosomal aberration study: 0, 40, 80, 160 µg/mL in the absence of S9 mix and 0, 70, 140, 280 µg/mL in the presence of S9 mix; Chromosomal aberration study (confirmatory study): 0, 80, 110, 140 µg/mL in the absence of S9 mix and 0, 140, 200, 260 µg/mL in the presence of S9 mix
SPINDLE INHIBITOR: Colcemid
STAIN: Giemsa
NUMBER OF REPLICATIONS: duplicate
NUMBER OF CELLS EVALUATED: cell growth inhibition study: 50 metaphase cells; chromosomal aberration study: 100 cells per dish.
OTHER EXAMINATIONS:
- Determination of polyploidy: yes
DETERMINATION OF CYTOTOXICITY
- Cell growth rate - Evaluation criteria:
- The study result was regarded as positive if incidence of cells with structural or numerical aberrations increased 10% or more and increases in the incidence were dose-dependent or if 5% of higher incidence was shown to be reproducible. Otherwise, the result was regarded as negative. If the result was judged to be positive, the D20 value (concentration at which 20% or more cells show abnormality) was determined.
- Statistics:
- Cell growth rates were calculated as percentages of the cell count in the negative control group, and concentrations at which 50% inhibition is achieve were calculated.
- Species / strain:
- mammalian cell line, other: Chinese Hamster Lung (CHL/IU)
- Metabolic activation:
- with and without
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- RANGE-FINDING/SCREENING STUDIES: The 50% inhibition concentration was about 140 µg/mL in the absence of S9 mix and about 250 µg/mL in the presence of S9 mix. Evidence of apparent inhibition of cell growth with cell growth rates lower than 50% was obtained at 160 µg/mL in the absence of S9 mix and 280 µg/mL in the presence of S9 mix, both the highest doses selected in the chromosomal aberration study. In addition, structural aberrations slightly increased in the absence of S9 mix.
CHROMOSOMAL ABERRATION STUDY
In the absence of S9-mix, the cell growth rate was 90.7%, 78.5% and 7.8%, respectively, at 40, 80 and 160 µg/mL. The incidence of structural aberrations was 0.5%, 0.5% and 15.5%, respectively, at 40, 80 and 160 µg/mL compared to 0% in the negative control group and 53.5% in the MMC (positive control) group. Incidence of numerical aberrations was less than 5.0% in all groups. The D20 value was calculated to be 0.23 mg/mL (S=0.016) in terms of structural aberrations. In the presence of S9-mix, the cell growth rate was 101.2%, 93.7% and 16.9%, respectively, at 70, 140 and 280 µg/mL.
The incidence of structural aberrations was 1.0%, 0% and 22.5%, respectively, at 40, 80 and 160 µg/mL compared to 0% in the negative control group and 32.0% in the MMC (positive control) group. The incidence of numerical aberrations was less than 5.0% in all groups. The D20 value was calculated to be 0.30 mg/mL (S=0.021) in terms of structural aberrations.
CONFIRMATORY STUDY
In the absence of S9-mix, the cell growth rate was 76.7%, 71.4% and 12.1%, respectively, at 80, 110 and 140 µg/mL. The incidence of structural aberrations was 1.0%, 0% and 19.0%, respectively, at 80, 110 and 140 µg/mL compared to 1.0% in the negative control group and 56.0% in the MMC (positive control) group. The incidence was less than 5.0% in all groups. The D20 value was calculated to be 0.21 mg/mL (S=0.019) in terms of structural aberrations. In the presence of S9-mix, the cell growth rate was 91.9%, 84.1% and 16.2%,respectively, at 140, 200 and 260 µg/mL. The incidence of structural aberrations was 2.5%, 5.0% and 23.5%, respectively, at 140, 200 and 260 µg/mL compared to 0% in the negative control group and 60.0% in the CPA (positive control) group. Incidence of numerical aberrations was 2.0%, 5.0% and 0%, respectively, at 140, 200 and 260 µg/mL compared to 0.5% in the negative control group. The D20 value was calculated to be 0.28 mg/mL (S=0.021) in terms of structural aberrations. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
positive
The test substance is considered to be clastogenic under the conditions of this test. - Executive summary:
In a GLP-compliant chromosome aberration test, Chinese Hamster Lung (CHL/IU) cells were exposed to the test substance with and without metabolic activation (S9 -mix).The study consisted of a cell growth inhibition test and two separate experiments. Except in the cell growth inhibition test, duplicate cultures of Chinese Hamster Lung (CHL) cells that had been treated with the test material in either the presence or absence of metabolic activation, were evaluated for induction of chromosome aberrations. Duplicate vehicle and positive controls were included in parallel in both experiments. In both experiments, the exposures were 6(18)-hour both with and without metabolic activation. The dose levels used were selected on the results of the cell growth inhibition test. The dose levels in experiment 1 were 0, 40, 80, 160 µg/mL in the absence of S9 mix and 0, 70, 140, 280 µg/mL in the presence of S9 mix. The dose levels in experiment 2 were 0, 80, 110, 140 µg/mL in the absence of S9 mix and 0, 140, 200, 260 µg/mL in the presence of S9 mix. Experiments were considered to have been conducted properly because there were no significant differences in the incidence of aberrant cells between two dishes used; incidence of aberrant cells was lower than 5% in the negative control group; and incidence of cells with aberrations other than gaps was 20% or higher in the positive control group. In the first experiment, chromosomal aberrations increased at the highest dose in both the presence and absence of S9 mix, but increases were not dose-dependent. In the second experiment, structural aberrations increased in both the presence and absence of S9 mix, showing reproducibility of the finding obtained in the first study. In addition, increases in structural aberrations were dose-dependent in the presence of S9 mix.In conclusion, the test material was considered to be clastogenic to CHL cells in vitro.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (positive)
Additional information
Ames test:
In a GLP compliant bacterial mutagenicity assay (Ames preincubation test), using four Salmonella typhimurium strains (TA 1535, TA 1537, TA 98, and TA 100) and one E. Coli WP2uvrA strain, the test substance was evaluated in the presence and absence of rat liver derived metabolic activation system (S9-mix). Two tests were performed. In the dose-finding study, the substance was tested in duplicate at 4.88, 19.5, 78.1, 313, 1250, and 5000 µg/platewith and without S9 mix.The main experiment was performed in duplicate dosing 156, 313, 625, 1256, 2500, 5000 µg/plate with and without S9 mix.The vehicle used was dimethyl sulphoxide. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. The revertant colony count on test substance-treated plates showed less than 2-fold increases compared to the spontaneous revertant colony count observed in the negative control group in the presence (metabolic activation method) and absence of liver S9 mix (non-metabolic activation method), indicating that the test substance has no mutagenic potential.
Chromosomal aberration test:
In a GLP-compliant chromosome aberration test, Chinese Hamster Lung (CHL/IU) cells were exposed to the test substance with and without metabolic activation (S9 -mix). The study consisted of a cell growth inhibition test and two separate experiments. Except in the cell growth inhibition test, duplicate cultures of Chinese Hamster Lung (CHL) cells that had been treated with the test material in either the presence or absence of metabolic activation, were evaluated for induction of chromosome aberrations. Duplicate vehicle and positive controls were included in parallel in both experiments. In both experiments, the exposures were 6(18)-hour both with and without metabolic activation. The dose levels used were selected on the results of the cell growth inhibition test. The dose levels in experiment 1 were 0, 40, 80, 160 µg/mL in the absence of S9 mix and 0, 70, 140, 280 µg/mL in the presence of S9 mix. The dose levels in experiment 2 were 0, 80, 110, 140 µg/mL in the absence of S9 mix and 0, 140, 200, 260 µg/mL in the presence of S9 mix. Experiments were considered to have been conducted properly because there were no significant differences in the incidence of aberrant cells between two dishes used; incidence of aberrant cells was lower than 5% in the negative control group; and incidence of cells with aberrations other than gaps was 20% or higher in the positive control group. In the first experiment, chromosomal aberrations increased at the highest dose in both the presence and absence of S9 mix, but increases were not dose-dependent. In the second experiment, structural aberrations increased in both the presence and absence of S9 mix, showing reproducibility of the finding obtained in the first study. In addition, increases in structural aberrations were dose-dependent in the presence of S9 mix. In conclusion, the test material was considered to be clastogenic to CHL cells in vitro.
Chromatid exchange assay:
2,4,6-Trimethylbenzaldehyde was tested in a sister chromatid exchange assay (Jansson 1988) using lymphocytes, collected from healthy non-smoking donors, mixed with Medium 199 containing Earle's salt. After 24 h incubation at 37°C the test substance was added to the culture. The cells were exposed to several concentrations between 0 and 1.0 mM. Styrene-7,8-oxide was used as a positive control. After 88 h of incubation at 37°C, cell divisions were blocked by colchicine for 2 hours. Subsequently, cells were treated with KCl and fixed in methanol/acetic acid. Chromosome preparations were made on slides and stained. 25 metaphases were scored and analysed per tested concentration. The dose-response data obtained was subjected to linear regression analysis by the method of least squares. It was concluded that the test substance induces sister chromatid exchanges.
Justification for classification or non-classification
There are two reliable studies available investigating the genotoxic potential of the test substance. The test substance is considered to be not mutagenic in the Ames test , but genotoxic in the chromosomal aberration test. In accordance with Directive 67/548/EEC and EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008, classification is not warrented, because the positive result was observed in vitro and structural analogues such as benzaldehyde (cas no: 100 -52 -7) and 3,4 -dimethylbenzaldehyde (cas no: 5973 -71 -7) are not genotoxic.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.